Geburtshilfe Frauenheilkd 2020; 80(10): e213
DOI: 10.1055/s-0040-1718204
Poster
Mittwoch, 7.10.2020
Gynäkologische Onkologie IV

(TA)MUC1 as a potential new target for breast cancer therapy

AS Heimes
1   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
,
P Fries
1   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
,
N Stergiou
2   UMC, VU University, Radiology and Nuclear Medicine, Radionuclide Center, Amsterdam, Niederlande
,
R Attariya
3   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Immunologie, Mainz, Deutschland
,
A Hasenburg
1   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
,
M Schmidt
1   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
,
E Schmitt
3   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Immunologie, Mainz, Deutschland
,
W Brenner
1   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
› Author Affiliations
 

Background One focus of breast cancer research is to identify new target structures for therapy. One such new target could be the tumor-associated glycoprotein (TA)MUC1, which differs from the glycoprotein MUC1 expressed on healthy cells. In the present study, the (TA)MUC1 expression was evaluated by immunohistochemistry.

Methods For (TA)MUC1 expression analyses a specific monoclonal antibody (GGSK-1/30) was created and 241 paraffin embedded breast cancer tumor slides were immunohistochemical evaluated. The staining was scored semi-quantitative using an IRS Score. For each specimen the product of staining intensity and portion of positive tumor cells was determined, which could assume IRS values between 0 and 12. Additionally, the subcellular localization of (TA)MUC1 was considered.

Results 237 of the 241 breast cancer samples were evaluable. In four cases, no invasive tumor cells were detectable in the section besides parts of a DCIS. In 235 cases (99.2 %) tumors were (TA)MUC1 positive. In healthy breast tissue no positive staining reaction was observed. The median IRS of (TA)MUC1 expression in tumor tissue was 8. In 74 % of the cases a mixed, predominantly cytoplasmic expression of (TA)MUC1 was found. In 14 % of the tumor sections a mixed, predominantly membrane-bound expression of (TA)MUC1 could be detected. Almost 12 % of the tumor slices showed an exclusively cytoplasmic expression.

Conclusion We were able to show that (TA)-MUC1 is reliably expressed in breast cancer specimens, whereas it is not detectable in healthy tissue. TA-MUC1 seems to be a promising target for the development of a targeted therapy.



Publication History

Article published online:
07 October 2020

© 2020. Thieme. All rights reserved.
Rüdigerstraße 14, 70469 Stuttgart, Germany